Back to top

Analyst Blog

Agenus Inc. (AGEN - Snapshot Report) announced encouraging final results from a phase II study (n=46) on Prophage autologous cancer vaccine. Shares of the company jumped over 10% following the announcement.

Prophage is being developed for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM). Results from the study revealed that the median overall survival of approximately 24 months was double in patients treated with Prophage vaccine along with standard of care treatment in comparison to standard of care treatment (gross total resection along with radiation and Merck’s (MRK - Analyst Report) Temodar alone). We note that the overall survival rate for the standard-of-care treatment is 14.6 months.

Results showed that half of the patients enrolled for the study lived for two years. Moreover results from the study showed that 33% of patients under the Prophage arm survived at 2 years and were continued to be studied for survival. Patients under Prophage treatment experienced a median progression-free survival of almost 18 months, significantly higher than in the standard of care arm.

GBM is the most common form of malignant brain tumor of which over 14,000 people die in the U.S. as per the American Cancer Society. We are encouraged by the study results.

We note that Agenus has another prophage series vaccine in its pipeline. The candidate is currently in a phase II study in combination with Roche’s (RHHBY - Analyst Report) Avastin in patients with surgically resectable recurrent glioma. We expect investor focus to remain on these candidates going forward.

Agenus carries a Zacks Rank #2 (Buy). Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) is a better-ranked stock with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%